Multiple Comparison Tests
Comparing the Survival Analysis of Two or More Groups
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Aug 9, 2025

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
Published on: June 30, 2014
Izanne Roos1, Ibrahima Diouf2, Sifat Sharmin2
1CORe, Department of Medicine, University of Melbourne, Melbourne, VIC, Australia/Neuroimmunology Centre, Department of Neurology, Royal Melbourne Hospital, Melbourne, VIC, Australia.
Propensity score matching and marginal structural models effectively compare fingolimod and natalizumab for multiple sclerosis (MS). Both methods showed natalizumab reduced relapse risk and improved disability, with no significant difference between techniques.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: